Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerMatti Annala, Kim N., Katherine Sunderland et al.|Cancer Discovery|2018Cited by 520
Outcomes in patients (Pts) with advanced prostate cancer and inactivating germline mutations in BRCA2 or ATM.Steven Yip, Kim N., Daniel Khalaf et al.|Journal of Clinical Oncology|2018Cited by 3
Predictors of germline DNA damage repair gene mutations (gDDRm) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).Steven Yip, Kim N., Alexander W. Wyatt et al.|Journal of Clinical Oncology|2019Cited by 1